INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
申请人:Dumas Jacques
公开号:US20120046290A1
公开(公告)日:2012-02-23
This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.
The C–S bond formation from arylhalides and thiols has been well established under various catalytic systems. In this work, user-friendly sulfinates have been exploited as an efficient sulfenylating reagent in the C–Scouplings through visible-light-induced photo/nickel dual catalysis under base- and external reductant-free conditions. A large number of aryl sulfide products were accessed with high
Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas
申请人:DUMAS Jacques
公开号:US20120129893A1
公开(公告)日:2012-05-24
Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
使用替代尿素化合物治疗由raf激酶介导的肿瘤的方法,以及这种化合物本身。
Regioselective Reduction of 3-Substituted <i>N</i>-Acylpyrazinium Salts toward the Synthesis of 1,2-Dihydropyrazines
作者:Alfred L. Williams、Valentine R. St. Hilaire、Tina Lee
DOI:10.1021/jo202498r
日期:2012.4.20
The regioselectivereduction of 3-substituted N-acylpyrazinium salts with n-Bu3SnH has been developed for the synthesis of 3-substituted 1,2-dihydropyrazines in yields of 56–94%. Substitution of the pyrazinium salts with electron-donating groups favors the formation of the 1,2-isomers as a result of their better stability over the 1,6-isomers. Under mild acidic conditions, 3-methoxy substituted 1,2-dihydropyrazine